{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-085566","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.192168+00:00","generated_at":"2026-06-17T09:21:13.373931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spero Therapeutics reports Q4 net income of $26.8M; GSK deal provides $66M upfront","bullets":["Q4 2022 net income $26.8M ($0.55 EPS) vs net loss $29.2M in Q4 2021; full-year net loss $46.4M ($1.23 loss per share).","Total revenue Q4 2022 $47.4M (up from $2.7M) driven by $46.1M collaboration revenue from GSK and Pfizer deals.","Cash and equivalents $109.1M as of Dec 31, 2022; company expects runway beyond 2024.","Initiated Phase 2 trial of SPR720 in NTM-PD; top-line data expected in first half of 2024.","GSK license for tebipenem HBr: $66M upfront, $9M equity investment, up to $525M milestones plus tiered royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-085566","json":"https://secwatch.observer/filing/0001193125-23-085566.json","markdown":"https://secwatch.observer/filing/0001193125-23-085566.md","text":"https://secwatch.observer/filing/0001193125-23-085566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/0001193125-23-085566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/d438825d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:21:13.373931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01ad760af4007914a83cc92961a17d7bee55f4e3","claim":"Spero Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Spero Therapeutics, Inc. (the \"Company\") issued a press release announcing its results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/0001193125-23-085566-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}